Free Trial

Vericel (NASDAQ:VCEL) Given Buy Rating at HC Wainwright

Vericel logo with Medical background

HC Wainwright reiterated their buy rating on shares of Vericel (NASDAQ:VCEL - Free Report) in a research report released on Friday morning,Benzinga reports. The brokerage currently has a $60.00 target price on the biotechnology company's stock.

Other equities analysts have also issued research reports about the company. BTIG Research lowered their price objective on Vericel from $56.00 to $55.00 and set a "buy" rating for the company in a research report on Monday, July 15th. Stephens boosted their price target on Vericel from $56.00 to $58.00 and gave the stock an "overweight" rating in a research report on Friday, August 2nd. TD Cowen raised their price objective on Vericel from $55.00 to $60.00 and gave the company a "buy" rating in a research report on Tuesday, August 27th. Canaccord Genuity Group initiated coverage on Vericel in a report on Friday, August 9th. They set a "buy" rating and a $57.00 price target for the company. Finally, StockNews.com cut shares of Vericel from a "hold" rating to a "sell" rating in a research note on Tuesday, October 8th. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, Vericel presently has an average rating of "Moderate Buy" and a consensus target price of $57.71.

View Our Latest Report on Vericel

Vericel Price Performance

NASDAQ:VCEL traded up $3.97 during mid-day trading on Friday, reaching $54.00. 645,309 shares of the company's stock traded hands, compared to its average volume of 429,835. Vericel has a 12-month low of $32.28 and a 12-month high of $54.47. The company has a 50 day moving average price of $44.22 and a 200-day moving average price of $46.34. The firm has a market capitalization of $2.65 billion, a price-to-earnings ratio of 893.17 and a beta of 1.66.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The company had revenue of $57.91 million during the quarter, compared to analyst estimates of $55.32 million. As a group, analysts forecast that Vericel will post 0.12 EPS for the current year.

Insider Activity

In other news, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the transaction, the director now directly owns 11,000 shares of the company's stock, valued at $443,850. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the sale, the director now owns 11,000 shares in the company, valued at $443,850. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Dominick Colangelo sold 17,500 shares of the firm's stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total value of $724,150.00. Following the transaction, the chief executive officer now owns 220,937 shares of the company's stock, valued at approximately $9,142,373.06. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 29,166 shares of company stock valued at $1,200,764 in the last quarter. 5.20% of the stock is currently owned by insiders.

Institutional Trading of Vericel

Hedge funds have recently made changes to their positions in the business. International Assets Investment Management LLC lifted its position in Vericel by 4,126.7% in the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company's stock worth $27,000 after buying an additional 619 shares during the last quarter. CWM LLC grew its holdings in Vericel by 319.0% during the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 504 shares during the last quarter. Farther Finance Advisors LLC raised its position in Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company's stock worth $53,000 after purchasing an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company's stock worth $77,000 after purchasing an additional 322 shares during the last quarter. Finally, Meeder Asset Management Inc. purchased a new position in shares of Vericel during the third quarter valued at approximately $92,000.

Vericel Company Profile

(Get Free Report)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Featured Stories

Analyst Recommendations for Vericel (NASDAQ:VCEL)

→ ⭕ [URGENT] Buy Alert just triggered (From Behind the Markets) (Ad)

Should you invest $1,000 in Vericel right now?

Before you consider Vericel, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.

While Vericel currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings: Can Blackwell Propel the Stock to $200+ in 2025?
These Top Stocks in 2024 Will Continue to be Big Winners in 2025
’Best Report in 2 Years’: NVIDIA Earnings Crushes Expectations Again

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines